EP0937089A1 - New knoevenagel condensation products, method for their production and their use - Google Patents
New knoevenagel condensation products, method for their production and their useInfo
- Publication number
- EP0937089A1 EP0937089A1 EP97951145A EP97951145A EP0937089A1 EP 0937089 A1 EP0937089 A1 EP 0937089A1 EP 97951145 A EP97951145 A EP 97951145A EP 97951145 A EP97951145 A EP 97951145A EP 0937089 A1 EP0937089 A1 EP 0937089A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- compounds according
- compounds
- treatment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Definitions
- the present invention relates to new Knoevenagel condensation products, processes for their production and their use, in particular for pharmaceutical and analytical purposes. Furthermore, conjugates of the Knoevenagel condensates with biomolecules are disclosed.
- the problem underlying the present invention was to provide new compounds which can be used in particular for pharmaceutical and analytical purposes.
- This object is achieved by the synthesis of the compound (Z) -5'-O-phosphonopyridoxidenidhhodanin (3), which is a derivative of the vitamin B6 coenzyme pyridoxal-5'-phosphate (1).
- Compound (3) is prepared by reacting (1) with the synthetic heterocyclic compound rhodanine (2) in a Knoevenagel condensation (cf. also Kesel et al., Tetrahedron 52 (1 8.1 1 .1 996), 14787-14800).
- Compound 3 is named (Z) -5 - [[5-hydroxy-6-methyl-3- [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone.
- the rhodanine portion of this molecule is able to bind to biomolecules such as single-stranded nucleic acids.
- the charged phosphate group ensures good water solubility.
- Compound 3 is subject to a (Z / E) stereoisomerism to form the (E) isomer 4. This cis / trans rearrangement is triggered, for example, by UV radiation with the wavelengths 254 nm and / or 366 nm.
- red 3-pyridinolate 5 in the form of a free acid, e.g. in pyridine or dimethyl sulfoxide (DMSO).
- the yellow compound 3 forms a deep red monosodium salt, the structure of which could be elucidated by X-ray structure analysis. It was crystallized as hemiheptadecahydrate (8.5 hydrate) and is present as (Z) - stereoisomer 6. When exposed to UV radiation, the monosodium salt 6 is also subject to the cis / trans rearrangement to the red (E) stereoisomer 7.
- Derivatives of compound 3 can be obtained by reaction with C 12 -C 18 fatty acid chlorides on the OH group.
- the present invention further relates to compounds of the general formula (8).
- X 1 , X 2 and X 3 are each independently selected from O, S and NR 5 ;
- R ⁇ R 2 , R 3 , R 4 and R 5 are each independently selected from any substituent;
- R 6 is selected from optionally substituted hydrocarbon radicals and O and n is 0 or 1; and salts, for example salts with alkali metal, alkaline earth metal or ammonium ions, hydrates and stereoisomers thereof, with the proviso that the compound is not pyridoxylidene rhodanine.
- X 1 is preferably O.
- X 2 is preferably NR 5 , where R 5 is hydrogen or CC 4 alkyl and particularly preferably hydrogen.
- X 3 is preferably S.
- Y is preferably S.
- Z is preferably CR 5 , where R 5 is hydrogen or C r C 4 alkyl and particularly preferably hydrogen.
- the substituents R 1 to R 4 can in themselves be any substituents provided that they are compatible with the overall structure.
- R 1 and R 2 or / and R 3 and R 4 can be bridged.
- the substituents R 1 to R 4 are hydrogen, halogen, hydroxyl, amine and optionally substituted alkyl radicals, for example C to C 6 alkyl, aminoalkyl, hydroxyalkyl, alkoxy etc.
- at least one of the substituents R to R 4 contains a sub physiologically negatively charged group, for example an acid group such as phosphate, carboxylate, sulfonate etc.
- the compounds of the general formula (8) are particularly preferably the (Z) -5-O-phosphonopyridoxylidene rhodanine (3), and salts, hydrates and stereoisomers thereof.
- the present invention further provides a process for the preparation of a compound of the general formula (8), characterized in that a compound of the formula (9)
- REPLACEMENT BUTT (RULE 26) wherein X 1 , X 2 , X 3 , Y, Z, R 1 -R 5 and R 6 are as defined for the compounds 8.
- the reaction is preferably carried out in an essentially equimolar ratio of 9 to 10 in a suitable solvent or solvent mixture.
- the temperature is preferably from room temperature to the reflux temperature of the solvent.
- the compounds of general formula (8) surprisingly have pharmaceutical activity.
- the invention thus furthermore relates to a pharmaceutical composition which contains as active ingredient a compound as stated above (preferably without taking into account the disclaimer in claim 1) and, if appropriate, pharmaceutically customary additives, auxiliaries, carriers and diluents.
- a first important application of the compounds according to the invention is the treatment of infectious diseases, for example viral infections, parasitic diseases, fungal diseases or bacterial diseases.
- infectious diseases for example viral infections, parasitic diseases, fungal diseases or bacterial diseases.
- viral infections in particular those viral infections which are caused by enveloped viruses, such as hepadnaviruses, herpes viruses or retroviruses, e.g. HIV.
- enveloped viruses such as hepadnaviruses, herpes viruses or retroviruses, e.g. HIV.
- the compounds according to the invention have also proven suitable for the treatment of diseases which are caused by other viruses, such as, for example, influenza or papilloma viruses.
- the compounds according to the invention have proven to be very suitable for controlling parasites such as, for example, Leishmania, Plasmodia or Trypanosomes.
- the compounds are most preferably used in HIV therapy, for example in combination therapy with other agents such as AZT or DDI.
- the compounds according to the invention are also used to combat tumor diseases, for example leukemia, in particular T-cell leukemia, or skin tumors such as malignant tumors.
- tumor diseases for example leukemia, in particular T-cell leukemia, or skin tumors such as malignant
- the compounds 8 also have immunomodulatory effects and are therefore suitable, for example, for the treatment of autoimmune diseases such as, for example, multiple sclerosis, Alzheimer's disease, lupus erythematosus, myasthenia gravis, chronic arthritis, type I diabetes, etc. and various neurodegenerative diseases.
- autoimmune diseases such as, for example, multiple sclerosis, Alzheimer's disease, lupus erythematosus, myasthenia gravis, chronic arthritis, type I diabetes, etc. and various neurodegenerative diseases.
- the compounds 8 are suitable for the treatment of diseases which exist in connection with disorders of the vitamin B metabolism, e.g. as a vitamin B6 antagonist.
- the compounds of the invention act as effectors, e.g. Activators, inhibitors or modifiers, on enzymatic reactions of the caspase system, and in particular as inhibitors of nitrogen monoxide synthases.
- compounds 8 can influence the secretion of TNF ⁇ in T lymphocytes. They are also able to bind to the cellular CD38 receptor, thereby inhibiting the binding of HIV gp41. In this way, the signal transmission path is decoupled from CD38, which leads to an inhibition of syncytia formation, NO release, T cell death by apoptosis, and single cell lysis.
- the compounds according to the invention can be used as such for therapeutic purposes. However, they can also be used as chelates with polyvalent metal ions or as noncovalent and / or covalent conjugates with biomolecules, for example nucleic acids, proteins, lipids, fatty acids etc.
- the pharmaceutical compositions according to the invention can be in any form, for example as creams, ointments, injectable or orally administrable liquids, liposomal formulations, tablets, dragées, capsules etc.
- the application can be, for example, locally or systemically, topically, orally or by injection.
- the dosage can be varied within a wide range, for example from 0.01 ⁇ g to 1 mg per kg of body weight, depending on the type of disease and application.
- the compounds according to the invention are also suitable as detection reagents.
- they can be used in the form of radioactive, for example with 3 H, 14 C, 32 P or 35 S-labeled derivatives.
- use in unlabelled form is preferred, since its strong coloring or fluorescent properties make it easy to detect in biological systems.
- the compounds according to the invention are therefore suitable for the detection of biomolecules, for example in diagnostic analysis methods, for example for the detection of single-stranded nucleic acids.
- the compounds are also suitable for structure elucidation, for example for sequencing proteins or nucleic acids.
- the compounds according to the invention can also be used for electrochromic applications, e.g. can be used as molecular digital switch substances or indicators for pH value, temperature and solvent.
- the compounds or derivatives thereof according to the invention are suitable as absorbers for ions, organic substances etc. or due to their intense colors and reversible color changes for decorative applications.
- the alkaline earth metal salts for example Mg or Ca salts of the compounds, which are in the form of gels.
- nanotechnology where, for example, individual fluorescent dye molecules and biomolecule derivatives excited with laser systems are detected and detected by sensitive detection systems, for example CCD cameras or avalanche detectors and optical techniques on thin-layer plates, in membranes, cells, drops, capillaries, etc. can be located.
- sensitive detection systems for example CCD cameras or avalanche detectors and optical techniques on thin-layer plates, in membranes, cells, drops, capillaries, etc.
- Further possibilities for single-molecule localization are optical scanning near-field microscopy on mini chips, confocal microscopy in polyacrylamide gels, for example 2-dimensional or multidimensional gel electophoresis of nucleic acids.
- the present invention also relates to derivatives of the compounds (8) which result from hydrolytic degradation and have, for example, the general formulas 11, 12 or 13:
- Fig. 1 the protection of cells against HIV infection mediated by compound (3).
- Fig.2 a schematic representation of hydrolysis by-products that arise during the synthesis of compound (3)
- REPLACEMENT BUTT (RULE 26) The mixture is boiled on a water bath with stirring under reflux. The pyridoxal-5'-phosphate monohydrate now slowly goes into solution and an initially yellow, then orange, then red suspension is formed. After boiling for 20 minutes, 1 50 ml of water are added through the cooler because the suspension begins to belch. The mixture is heated for a further 10 min, during which the red reaction product precipitates and leads to belching. Then refrigerate in the freezer at a temperature of - 18 ° C for no more than 2 hours.
- the orange product is filtered off, transferred with the mother liquor and with 100 ml of ice-cold abs. Washed ethanol. Vacuum drying in a desiccator over anhydrous calcium chloride; Yield: 9.85 g of orange-yellow crude product (Z) -5 - [[5-hydroxy-6-methyl-3- [phosphonooxy) methyl] -4-pyridinyl] - methylene] -2-thioxo-4-thiazolidinone.
- the product contains educts, by-products and, despite vacuum drying, ethanol and water.
- the analysis of compound 3 comprises 1 H-NMR spectroscopy, 13 C-NMR spectroscopy, 31 P-NMR spectroscopy, RP-18 HPLC, fast atom bombardment mass spectrometry (FAB MS), IR spectroscopy, UV spectrophotometry and fluorescence spectrophotometry. Typical analytical data of compound 3 follow.
- Compounds 3 and 6 can be used in radiolabelled form, for example labeled with 3 H, 14 C, 32 P or 35 S, as probes for the detection of single-stranded nucleic acids.
- the substances 3/6 can also be used for the fluorescence detection of single-stranded DNA.
- the (E) stereoisomer 4 fluoresces in DSMO, the (Z) stereoisomer in water significantly less.
- the (E) stereoisomer 4 is bound to single-stranded DNA, single-stranded DNA can be detected when fluorescence occurs after extraction with DMSO.
- the wavelength used for excitation is in the range from 420 to 500 nm, the emission in DMSO or pyridine is 575 nm.
- Substance 6 inhibits the neuronal, endothelial and immunologically / - inducible isoforms of nitrogen monoxide synthase (NOS).
- the inhibition constant (IC 50 ) for nNOS is 61.25 ⁇ M.
- the inhibition constant (IC 50 ) is 50 ⁇ M.
- Substance 3 can be used in radioactively labeled or unlabelled form for the two-dimensional electrophoretic separation of single-stranded nucleic acids. In the first dimension there can be a separation according to the charge and in the second dimension a separation according to the molecular size. Compound 3 can be associatively or covalently coupled to the nucleic acid.
- Substance 3 and derivatives thereof are effective as therapeutic agents, in particular for influencing the propagation processes of infectious agents, e.g. from those that occur in the host with intermediates as single-stranded DNA, such as retroviruses, herpes viruses or hepatoviruses.
- Myeloid HUT78 cells are exposed to HIV infection in the absence or in the presence of 1, 87 mM or 0, 1 87 mM compound 3.
- the HIV detection is carried out by photometric determination of the p24 antigen. From Figure 1 it can be seen that no p24 was detectable in the cells treated according to the invention, whereas in the control the p24 test was positive from the seventh day.
- Total remission is found a few hours after local application to the affected skin.
- a patient (51 years, male) with virus flu is orally treated with a few drops of an H 2 O / DMSO solution of compound 3 (approx. 1 ⁇ g / ml). The disease symptoms disappeared overnight.
- the (Z / E) stereoisomerism of compound 3 occurs depending on the temperature (thermochromism) and depending on the solvent (solvatochromism). 3 can therefore be used as a temperature indicator and / or solvent indicator.
- the (Z / E) stereoisomerism of compounds 3 and 4 occurs depending on the application of an electric field (electrochromism). Therefore 3 can be used as a digital switching element due to the different fluorescence spectroscopic properties compared to 4 e.g. when excited by laser light with a wavelength of 480 nm. Thereby, after applying an electric field to 3, rearrangement in 4 occurs and thus fluorescence emission up to 575 nm after excitation at 480 nm.
- Compound 3 can act in metabolism as an antagonist of the coenzyme pyridoxal-5'-phosphate by binding to the enzymes which require this coenzyme and therefore have tumor-inhibiting properties. - 1 7 -
- Compound 3 can be used for the proliferation control / chemotherapy / cytostatic therapy of malignant tumors in local application to skin tumors (malignant melanoma, Karposi sarcoma), possibly in combination with UV radiation, and / or for the proliferation control of other skin diseases with an increased cell division rate (e.g. Psoriaris) can be used.
- the binding of compound 3 to replication-active single-stranded DNA regions can be photochemically fixed by UV radiation and leads to locally limited cytotoxicity.
- Compound 3 due to its coloring and fluorescent properties, as well as its ability to couple to biomolecules, e.g. Proteins are used for structure elucidation, e.g. for amino acid sequence determination of proteins or for DNA sequencing.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19645974 | 1996-11-07 | ||
DE19645974A DE19645974C1 (en) | 1996-11-07 | 1996-11-07 | (Z) -5 - [[3-Hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone, process for its preparation and use |
PCT/EP1997/006184 WO1998020013A1 (en) | 1996-11-07 | 1997-11-07 | New knoevenagel condensation products, method for their production and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0937089A1 true EP0937089A1 (en) | 1999-08-25 |
Family
ID=7810958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97951145A Withdrawn EP0937089A1 (en) | 1996-11-07 | 1997-11-07 | New knoevenagel condensation products, method for their production and their use |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0937089A1 (en) |
JP (1) | JP2001503752A (en) |
KR (1) | KR20000053141A (en) |
CN (1) | CN1236369A (en) |
AU (1) | AU728345B2 (en) |
BR (1) | BR9712930A (en) |
CA (1) | CA2270973A1 (en) |
CZ (1) | CZ160999A3 (en) |
DE (1) | DE19645974C1 (en) |
HU (1) | HUP9904289A3 (en) |
IL (1) | IL129826A0 (en) |
NO (1) | NO992209L (en) |
NZ (1) | NZ335977A (en) |
PL (1) | PL333128A1 (en) |
SK (1) | SK61799A3 (en) |
TR (1) | TR199901733T2 (en) |
WO (1) | WO1998020013A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1305485A (en) * | 1998-05-04 | 2001-07-25 | 安德里斯·约翰尼斯·凯塞尔 | Monomeric, oligomeric acid polymeric knoevenagel condensation products |
BR9913157A (en) * | 1998-08-21 | 2001-05-15 | Viropharma Inc | Processes for treating or preventing infection caused by at least one virus of the flaviviridae and diseases associated with said infection and infection caused by at least one virus of the genus hepacivirus of flavivirity and diseases associated with said infection, pharmaceutical composition to treat or prevent viral infections , it's composed |
EP1173451A1 (en) * | 1999-04-30 | 2002-01-23 | Walter Oberthür | New antioxidative vitamin b 6 analogs |
US6940497B2 (en) | 2001-10-16 | 2005-09-06 | Hewlett-Packard Development Company, L.P. | Portable electronic reading apparatus |
US20030071780A1 (en) * | 2001-10-16 | 2003-04-17 | Vincent Kent D. | High resolution display |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9103776D0 (en) * | 1991-12-19 | 1991-12-19 | Astra Ab | NEW COMPOUNDS |
IT1266570B1 (en) * | 1993-07-30 | 1997-01-09 | Zambon Spa | DERIVATIVES OF PROPANAMIDE N-ETEROARYL SUBSTITUTES USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES |
FR2722790B1 (en) * | 1994-07-19 | 1996-10-04 | Roussel Uclaf | NOVEL CEPHALOSPORINS COMPRISING IN POSITION 7 A SUBSTITUTED RADICAL BENZYLOXYMINO, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
-
1996
- 1996-11-07 DE DE19645974A patent/DE19645974C1/en not_active Expired - Fee Related
-
1997
- 1997-11-07 EP EP97951145A patent/EP0937089A1/en not_active Withdrawn
- 1997-11-07 WO PCT/EP1997/006184 patent/WO1998020013A1/en not_active Application Discontinuation
- 1997-11-07 IL IL12982697A patent/IL129826A0/en unknown
- 1997-11-07 PL PL97333128A patent/PL333128A1/en unknown
- 1997-11-07 BR BRPI9712930-5A patent/BR9712930A/en not_active IP Right Cessation
- 1997-11-07 CZ CZ991609A patent/CZ160999A3/en unknown
- 1997-11-07 NZ NZ335977A patent/NZ335977A/en unknown
- 1997-11-07 JP JP52107198A patent/JP2001503752A/en active Pending
- 1997-11-07 AU AU54798/98A patent/AU728345B2/en not_active Revoked
- 1997-11-07 TR TR1999/01733T patent/TR199901733T2/en unknown
- 1997-11-07 KR KR1019990704073A patent/KR20000053141A/en not_active Application Discontinuation
- 1997-11-07 CN CN97199496A patent/CN1236369A/en active Pending
- 1997-11-07 SK SK617-99A patent/SK61799A3/en unknown
- 1997-11-07 HU HU9904289A patent/HUP9904289A3/en unknown
- 1997-11-07 CA CA002270973A patent/CA2270973A1/en not_active Withdrawn
-
1999
- 1999-05-06 NO NO992209A patent/NO992209L/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9820013A1 * |
Also Published As
Publication number | Publication date |
---|---|
CZ160999A3 (en) | 1999-09-15 |
CN1236369A (en) | 1999-11-24 |
CA2270973A1 (en) | 1998-05-14 |
DE19645974C1 (en) | 1998-08-13 |
PL333128A1 (en) | 1999-11-22 |
KR20000053141A (en) | 2000-08-25 |
BR9712930A (en) | 2006-04-18 |
JP2001503752A (en) | 2001-03-21 |
IL129826A0 (en) | 2000-02-29 |
HUP9904289A2 (en) | 2001-04-28 |
SK61799A3 (en) | 2000-01-18 |
NO992209D0 (en) | 1999-05-06 |
HUP9904289A3 (en) | 2001-08-28 |
NO992209L (en) | 1999-07-01 |
NZ335977A (en) | 2000-12-22 |
TR199901733T2 (en) | 1999-09-21 |
AU5479898A (en) | 1998-05-29 |
AU728345B2 (en) | 2001-01-04 |
WO1998020013A1 (en) | 1998-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2815724A1 (en) | INDOLDER DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM | |
DE3319992C2 (en) | ||
EP0313874B1 (en) | Disulfur analogs of LL-E33288 antitumor agents | |
EP0901501B1 (en) | Nucleoside derivatives with photo-unstable protective groups | |
DE2424119A1 (en) | MYCOPHENOLIC ACID DERIVATIVES, THE PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
WO1998039334A1 (en) | Dna glycosylase inhibitors, and uses related thereto | |
Iyengar et al. | Preparation and antitumor activity of 7-substituted 1, 2-aziridinomitosenes | |
DE3413489C2 (en) | ||
EP0937089A1 (en) | New knoevenagel condensation products, method for their production and their use | |
JPS6126996B2 (en) | ||
WO1998020013A9 (en) | New knoevenagel condensation products, method for their production and their use | |
Jaycox et al. | Potential DNA bis‐intercalating agents: Synthesis and antitumor activity of novel, conformationally restricted bis (9‐aminoacridines) | |
WO2004081023A1 (en) | Solubilization method of water-insoluble curcumin | |
HU193339B (en) | Process for producing amino-anthracene-dion-platinum-complexes | |
CN114656453A (en) | Heptamethine indole cyanine-TEMPO chemical couple chain small molecule, preparation method and application thereof in preparing radioprotection preparation | |
EP0521353B1 (en) | Antineoplastic medicament containing octadecyl-[2-(N-methylpiperidino)-ethyl] phosphate and synthesis thereof | |
DE2729165C2 (en) | Phenethylamine derivatives and their salts, processes for their preparation and pharmaceutical compositions containing them | |
US11479570B2 (en) | Pentafluorophosphate derivative, its uses and an appropriate manufacturing method | |
HU192977B (en) | Process for the production of /1,2-diphenyl-ethylene-diamine/-platinum/ii-complex-derivates | |
DE10201228A1 (en) | New 10-benzylidene-9(10H)-anthracenones, are tubulin polymerization inhibitors useful for treating proliferative diseases, e.g. psoriasis, protozoal infections or especially cancer | |
Murdock et al. | N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity | |
EP1758904B1 (en) | Flavopereirine derivatives for cancer therapy | |
HU179949B (en) | Process for preparing nitroso-carbamide derivatives | |
EP0302181B1 (en) | A process for preparing platinum-(ii)-cis-dichlorobis-(trishydroxymethylphosphine) | |
US9873699B1 (en) | Anti-cancer agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990531 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 19990531;LV PAYMENT 19990531;RO PAYMENT 19990531;SI PAYMENT 19990531 |
|
17Q | First examination report despatched |
Effective date: 20010611 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20030122 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1022698 Country of ref document: HK |